Has Joseph Yi received payments from drug or device companies?

Yes. Drug and device makers reported $2,060 in general payments to Joseph Yi across 111 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Joseph Yi did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Joseph Yi come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Joseph Yi

Psychiatry · Philadelphia, PANPI 1083875124

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 27.4% of the total. 2025 is the largest year on record at $711, 3.2 times the $219 reported in 2019.

$2,060in general payments, 2019–2025

Across 111 payments — averaging $18.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$564
Merck$484
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$147
Otsuka America Pharmaceutical, Inc.$109
Corium, LLC$94
E.r. Squibb & Sons, L.L.C.$82
plus $579 from 15 others

What the payments were for

Food & beverage$2,060100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	34	$564
Merck	29	$484
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	6	$147
Otsuka America Pharmaceutical, Inc.	6	$109
Corium, LLC	3	$94
E.r. Squibb & Sons, L.L.C.	3	$82
Supernus Pharmaceuticals, Inc.	4	$75
Ironshore Pharmaceuticals Inc.	3	$71
Axsome Therapeutics, Inc.	3	$52
Gilead	2	$50
Neurocrine Biosciences, Inc.	2	$50
Tris Pharma Inc	3	$46
Johnson & Johnson	3	$44
Indivior Inc.	2	$36
Collegium Pharmaceutical, Inc.	2	$33
Braeburn Inc.	1	$29
Vanda Pharmaceuticals Inc.	1	$26
Janssen Scientific Affairs, LLC	1	$20
Alkermes, Inc.	1	$19
Vertical Pharmaceuticals, LLC	1	$17
Takeda Pharmaceuticals U.S.A., Inc.	1	$11

How this compares

$2,060 in reported general payments places this provider in the 85th percentile of 1,838 psychiatry providers in Pennsylvania.

See all psychiatry providers in Pennsylvania →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Lorazepam	12	$65
Citalopram HbrCitalopram Hydrobromide	12	$22

Paid to pharmacies, not to this prescriber.

Other psychiatry in Philadelphia

Daniel WeintraubPhiladelphia$647K
Michael ThasePhiladelphia$396K
Freddy AliPhiladelphia$107K
Richard JaffePhiladelphia$101K
Ramesh EluriPhiladelphia$85K
John LaurielloPhiladelphia$62K
Sidra GhafoorPhiladelphia$56K
Maria OquendoPhiladelphia$50K
David OslinPhiladelphia$30K
Bianca PrevidiPhiladelphia$28K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →